Peptides for Longevity: BPC-157, TB-500, Epithalon, and What the Evidence Shows

What Peptides Are#

Peptides are short chains of amino acids — smaller than full proteins, typically 2–50 amino acids in length. The body naturally produces thousands of peptides as signalling molecules: hormones (insulin is a peptide), growth factors, neurotransmitters, and immune modulators are all peptides.

Synthetic therapeutic peptides mimic or enhance these natural signalling processes. Because they are targeted signalling molecules rather than broad pharmacological agents, they can in theory produce specific effects with fewer systemic side effects than traditional drugs.

Peptide therapy is not new — insulin, glucagon, and oxytocin are peptides that have been used medically for decades. The longevity peptide space focuses on compounds that may promote tissue repair, reduce inflammation, improve hormonal profiles, and potentially slow ageing processes.

Critical regulatory context: Most peptides discussed in longevity and biohacking communities are:

• Not FDA-approved for the uses described
• Classified as research chemicals (legal to purchase for research, legally ambiguous for personal use)
• Available from compounding pharmacies (with a prescription) or research chemical suppliers (no prescription)
• Not subject to the quality control standards of pharmaceutical drugs

This guide is informational. Peptide use carries genuine risks and should be undertaken only with full understanding of the regulatory landscape and, where possible, with physician oversight.

---

BPC-157 (Body Protection Compound 157)#

What It Is#

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring protein found in gastric juice. It was isolated and studied primarily by Croatian researcher Predrag Sikiric, whose group has published extensively on its effects.

Evidence#

Animal studies (extensive): BPC-157 has been studied in rodents for 30+ years. Consistent findings across hundreds of papers:

• Accelerated healing of tendons, ligaments, muscles, and bone
• Gut healing — reduces intestinal damage from NSAIDs, alcohol, and inflammatory bowel disease models
• Neuroprotection — reduces brain damage in stroke and traumatic brain injury models
• Cardiovascular effects — reduces blood pressure, improves heart function after injury
• Anti-inflammatory effects across multiple tissue types
• Promotes angiogenesis (new blood vessel formation) at injury sites

Human evidence: Almost none. There are no published human RCTs for BPC-157 as of 2024. One phase II trial was conducted in Croatia for inflammatory bowel disease — the results were not published (this is a significant concern — unpublished trials often indicate negative or inconclusive results).

Mechanism: BPC-157 appears to act via nitric oxide pathways (explaining the vascular effects), growth hormone receptor interaction, and upregulation of growth factors at injury sites (VEGF, EGF). It does not appear to work through a single target — the broad effects suggest systemic modulation of healing processes.

Use in Longevity and Athletic Communities#

BPC-157 is widely used (with significant anecdotal reporting) for:

• Tendon and ligament injuries (the most common reported use)
• Gut healing and IBD symptom relief
• Systemic anti-inflammatory effects
• Neurological injury recovery

Routes of administration:

• Subcutaneous injection at the injury site (most common; most evidence)
• Oral/capsule (lower bioavailability but gut-targeted effects)
• Nasal spray (for neurological or systemic effects)

Dose: Typically 200–500 mcg/day injected subcutaneously, 4–12 weeks for acute injury

Honest Assessment#

The animal evidence for BPC-157 is extensive and consistently positive — to a degree that is unusual for a compound that has received so little human study. The absence of human trials after 30+ years of animal research is puzzling; cynically, a compound that cannot be patented (natural-derived peptides) has less commercial incentive for expensive clinical trials.

The anecdotal evidence from the athletic and biohacking communities is extensive. Many elite athletes and coaches report remarkable healing outcomes. This evidence is not scientific but the volume and consistency is notable.

Risks: The primary risks are:

• Unknown human pharmacology (effects not confirmed in controlled trials)
• Quality control issues with grey market peptide suppliers (purity, sterility)
• Injection site complications (infection risk if not prepared with medical-grade sterility)
• Unknown long-term effects

BPC-157 is not recommended without physician oversight and access to pharmaceutical-grade compounded product.

---

TB-500 (Thymosin Beta-4)#

What It Is#

TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein found throughout the body that regulates actin — the protein involved in cell movement, muscle contraction, and wound healing.

Evidence#

Animal studies: TB-500 promotes:

• Cardiac repair after heart attack — reduces scar tissue, regenerates heart muscle
• Wound healing and tissue repair
• Neurological recovery (promotes neurogenesis and axon regrowth)
• Corneal healing
• Angiogenesis at injury sites

Human evidence: One phase II trial in heart failure patients showed improved exercise tolerance. No published RCTs for musculoskeletal or neurological applications.

Comparison with BPC-157#

TB-500 and BPC-157 are often used together (a common protocol in the biohacking community). They appear to have complementary mechanisms:

• BPC-157: primarily acts via nitric oxide and growth factor upregulation
• TB-500: primarily acts via actin regulation and stem cell migration

Used together: anecdotally reported to produce significantly faster tissue repair than either alone. No controlled human data.

---

Epithalon (Epitalon)#

What It Is#

Epithalon is a tetrapeptide (4 amino acids: Ala-Glu-Asp-Gly) derived from the pineal gland extract epithalamin. It was developed in Russia in the 1980s–1990s by Vladimir Khavinson, who has published extensively on its effects.

The Longevity Evidence#

Epithalon is arguably the most directly "longevity" peptide available — its primary documented effects are on telomere length and biological ageing.

Animal lifespan studies:

• Epithalon extended lifespan in mice and rats by 15–25% in multiple studies from Khavinson's group
• Extended lifespan in fruit flies
• Reduced tumour incidence in aged animals

Telomere effects: Epithalon activates telomerase — the enzyme that extends telomeres. In cell culture and animal studies, Epithalon treatment:

• Increases telomere length in lymphocytes
• Reduces DNA oxidative damage
• Reduces age-related chromosomal aberrations

Human studies (observational): Khavinson's group published several studies on elderly humans receiving Epithalon via courses of injections over years. They report:

• Reduced mortality in treated vs untreated elderly cohorts
• Improved immune function markers
• Reduced incidence of cardiovascular disease and cancer

Honest limitation: Khavinson's work is primarily from his own institute, published mostly in Russian journals, with limited independent replication. The human studies lack rigorous randomisation and blinding. The data is intriguing but far below the standard required for clinical adoption in Western medicine.

Melatonin relationship: The pineal gland connection is significant. Epithalon appears to restore melatonin production and regulate the pineal gland's function — an effect that could explain many of its reported anti-ageing effects through circadian and antioxidant mechanisms.

Administration#

Epithalon is typically used in courses:

• 5–10 mg/day via subcutaneous injection or intranasal
• 10–20 day courses, repeated 2–4 times per year

Some longevity physicians include Epithalon in anti-aging protocols; it has a significant following in Russia and Eastern Europe where Khavinson's work has more institutional acceptance.

---

Other Notable Peptides in Longevity Medicine#

GHK-Cu (Copper Peptide)#

A naturally occurring tripeptide that activates genes associated with tissue repair, anti-inflammatory response, and antioxidant defence. Found in human blood plasma (declines significantly with age).

Evidence: Strong cell culture evidence; promising animal studies; limited human RCT data. Used extensively in topical skincare (copper peptide serums) for wound healing and anti-ageing — topical evidence is stronger than systemic.

Use: Topical (most accessible and most evidence); subcutaneous injection (more research-chemical territory).

Semaglutide/Tirzepatide (GLP-1 Agonists)#

Not classic research peptides — these are FDA-approved pharmaceuticals that happen to be peptide-based. GLP-1 agonists (Ozempic, Wegovy, Mounjaro) produce weight loss, cardiovascular risk reduction, and metabolic improvement that overlaps significantly with longevity goals.

Attia and others note that the cardiovascular outcome data from GLP-1 agonist trials (LEADER, SUSTAIN-6, SURMOUNT) represents some of the most significant longevity evidence of any drug class. For people with significant insulin resistance or obesity, GLP-1 agonists are now in many longevity physicians' protocols.

Requires prescription; FDA-approved; very different risk profile from research peptides.

CJC-1295 / Ipamorelin (Growth Hormone Releasing Peptides)#

These peptides stimulate growth hormone release from the pituitary. Used to increase GH levels without exogenous HGH (which is controlled and carries significant risks).

Evidence: Moderate for GH elevation; limited for longevity outcomes specifically. Used in anti-aging clinics for lean mass preservation, fat metabolism, and sleep quality improvement.

Caution: Stimulating GH raises IGF-1, which is a double-edged sword — too high IGF-1 is associated with accelerated ageing and cancer risk.

---

Sourcing and Safety#

The quality control problem: Peptides purchased from research chemical suppliers vary enormously in purity, actual peptide content, and sterility. Several independent analyses of commercially available BPC-157 and TB-500 found significant discrepancies from claimed contents.

Safer options:

• Compounding pharmacies with physician prescription — pharmaceutical-grade sterility and purity
• US-based peptide research suppliers with COAs (certificates of analysis) from independent third-party labs

Sterile technique: Injectable peptides require sterile preparation — bacteriostatic water, insulin syringes, alcohol swabs, and proper injection technique. Improper preparation causes infection. This is not optional.

Physician involvement: Working with a physician experienced in peptide therapy provides prescription access to compounded pharmaceutical-grade peptides and appropriate monitoring.

---

Honest Bottom Line#

Peptides occupy a unique space in longevity medicine: mechanistically compelling, animal evidence strong, human evidence thin, regulatory status grey, quality control variable.

The most intellectually honest position is that peptides — particularly BPC-157 for injury and Epithalon for longevity — have enough evidence to warrant serious research attention and cautious personal exploration under medical supervision, but not enough evidence to strongly recommend to most people who are not yet optimising the established fundamentals (sleep, exercise, nutrition, stress, basic supplementation).

For someone who has their fundamentals dialled in and wants to explore the frontier, peptides are among the most interesting tools available. For someone still working on consistent sleep and exercise, peptides should wait.